CD8A and cancer: The prostate cancer vaccine alone was unable to cause complete tumor regression, which could reflect either that the initial CD8+ T-cell-mediated antitumor immune response simply is not potent enough to completely eliminate all the cancer cells or that the cancer cells have lost their immunogenicity.